185 related articles for article (PubMed ID: 38287441)
1. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
Nie J; Dang S; Zhu R; Lu T; Zhang W
Breast Cancer Res; 2024 Jan; 26(1):19. PubMed ID: 38287441
[TBL] [Abstract][Full Text] [Related]
2. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
[TBL] [Abstract][Full Text] [Related]
3. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
4. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
5. Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.
Dong Y; Van Tine BA; Oyama T; Wang PI; Cheng EH; Hsieh JJ
Cell Res; 2014 Nov; 24(11):1354-66. PubMed ID: 25267403
[TBL] [Abstract][Full Text] [Related]
6. P190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis.
McHenry PR; Sears JC; Herrick MP; Chang P; Heckman-Stoddard BM; Rybarczyk M; Chodosh LA; Gunther EJ; Hilsenbeck SG; Rosen JM; Vargo-Gogola T
Breast Cancer Res; 2010; 12(5):R73. PubMed ID: 20860838
[TBL] [Abstract][Full Text] [Related]
7. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
8. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
9. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of ADAMTS18 promotes cell migration and invasion of breast cancer through AKT and NF-κB signaling.
Xu H; Xiao Q; Fan Y; Xiang T; Li C; Li C; Li S; Hui T; Zhang L; Li H; Li L; Ren G
Cancer Med; 2017 Jun; 6(6):1399-1408. PubMed ID: 28503860
[TBL] [Abstract][Full Text] [Related]
11. USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
Kuang X; Salinger A; Benavides F; Muller WJ; Dent SYR; Koutelou E
PLoS One; 2024; 19(1):e0290837. PubMed ID: 38236941
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H
Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
[TBL] [Abstract][Full Text] [Related]
14. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
[TBL] [Abstract][Full Text] [Related]
15. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.
Dearth RK; Kuiatse I; Wang YF; Liao L; Hilsenbeck SG; Brown PH; Xu J; Lee AV
BMC Cancer; 2011 Aug; 11():377. PubMed ID: 21867536
[TBL] [Abstract][Full Text] [Related]
16. Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium.
Tarulli GA; De Silva D; Ho V; Kunasegaran K; Ghosh K; Tan BC; Bulavin DV; Pietersen AM
Breast Cancer Res; 2013 Jan; 15(1):R10. PubMed ID: 23369183
[TBL] [Abstract][Full Text] [Related]
17. Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.
Ikink GJ; Boer M; Bakker ERM; Vendel-Zwaagstra A; Klijn C; Ten Hoeve J; Jonkers J; Wessels LF; Hilkens J
Oncogene; 2018 Mar; 37(12):1594-1609. PubMed ID: 29326437
[TBL] [Abstract][Full Text] [Related]
18. The secreted protease Adamts18 links hormone action to activation of the mammary stem cell niche.
Ataca D; Aouad P; Constantin C; Laszlo C; Beleut M; Shamseddin M; Rajaram RD; Jeitziner R; Mead TJ; Caikovski M; Bucher P; Ambrosini G; Apte SS; Brisken C
Nat Commun; 2020 Mar; 11(1):1571. PubMed ID: 32218432
[TBL] [Abstract][Full Text] [Related]
19. Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.
So JY; Wahler JE; Yoon T; Smolarek AK; Lin Y; Shih WJ; Maehr H; Uskokovic M; Liby KT; Sporn MB; Suh N
Cancer Prev Res (Phila); 2013 Sep; 6(9):959-70. PubMed ID: 23856074
[TBL] [Abstract][Full Text] [Related]
20. Heat shock factor Hsf1 cooperates with ErbB2 (Her2/Neu) protein to promote mammary tumorigenesis and metastasis.
Xi C; Hu Y; Buckhaults P; Moskophidis D; Mivechi NF
J Biol Chem; 2012 Oct; 287(42):35646-35657. PubMed ID: 22847003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]